Bavachin Suppresses Cell Growth and Enhances Temozolomide Efficacy in U-87 MG Glioblastoma Cells

Glioblastoma multiform (GBM) is a lethal cancer affecting the central nervous system. Existing treatment methods for GBM include chemotherapy, radiation, and surgery. Temozolomide is a common chemotherapy treatment for GBM but causes unwanted side effects, as do most chemotherapy treatments. To decrease the harmful side effects of chemotherapy, research has turned to exploring natural compounds to treat cancer. In this study, the natural compound bavachin was investigated to determine cytotoxicity in GBM cells. Bavachin has been tested in many cell lines but not glioblastoma. A sulforhodamine B (SRB) assay, trypan blue counting, and a tumorsphere assay were used to test the hypothesis in this study. It was found that bavachin suppressed glioblastoma cell and tumorsphere viability, had a synergistic interaction with temozolomide, and ornithine decarboxylase was identified as a potential target in silico. This study demonstrated the ability of bavachin to suppress the growth of U-87 MG glioblastoma cells and enhance temozolomide efficacy. These findings demonstrated that bavachin is a potential treatment for GBM based on its ability to suppress cell growth. KEYWORDS: Glioblastoma Multiforme; Temozolomide; Bavachin; Flavonoid; Tumorspheres; Cell Viability; Cancer; Apoptosis; Psoralea corylifolia